Eli Lilly is in the process of separating its animal health drug manufacturing from the facilities used to make human pharmaceuticals, a move that sets the stage for spinoff.
Management, however, insists that the animal health division -- Elanco -- will remain part of Lilly, speaking at an investor conference earlier in the week. An Elanco spokeswoman told Bloomberg that the split was motivated by the fact that drugs for animals and humans have different manufacturing requirements.
Lilly started the split process in early 2015, after finalizing its buy of Novartis' animal health unit, which included 17 manufacturing sites.
Read the Bloomberg coverage